1. Home
  2. WEAV vs ALT Comparison

WEAV vs ALT Comparison

Compare WEAV & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Weave Communications Inc.

WEAV

Weave Communications Inc.

HOLD

Current Price

$5.20

Market Cap

487.7M

Sector

Technology

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$2.70

Market Cap

421.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WEAV
ALT
Founded
2011
1997
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
487.7M
421.5M
IPO Year
2021
2005

Fundamental Metrics

Financial Performance
Metric
WEAV
ALT
Price
$5.20
$2.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
6
Target Price
$11.00
$17.67
AVG Volume (30 Days)
861.8K
2.8M
Earning Date
04-30-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
7.50
25.37
EPS
N/A
N/A
Revenue
$239,024,000.00
$41,000.00
Revenue This Year
$17.20
N/A
Revenue Next Year
$13.74
N/A
P/E Ratio
N/A
N/A
Revenue Growth
16.99
105.00
52 Week Low
$4.24
$2.56
52 Week High
$9.10
$7.73

Technical Indicators

Market Signals
Indicator
WEAV
ALT
Relative Strength Index (RSI) 40.52 42.50
Support Level $4.93 $2.57
Resistance Level $5.56 $4.19
Average True Range (ATR) 0.29 0.12
MACD -0.08 -0.00
Stochastic Oscillator 9.82 27.34

Price Performance

Historical Comparison
WEAV
ALT

About WEAV Weave Communications Inc.

Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses, that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more, enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and revenue from subscription services.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: